154 results
8-K
EX-99.1
SEEL
Seelos Therapeutics Inc
19 Mar 24
Other Events
4:05pm
RELYVRIO® Free (ERF)1 data set (n=130), including:
a 22% improvement in slope of change in ALSFRS-R assessment adjusted for mortality, with an 89
DEFA14A
SEEL
Seelos Therapeutics Inc
22 Dec 23
Additional proxy soliciting materials
8:10am
) biomarker and Modified Scale for Assessment and Rating of Ataxia (m-SARA) scores appear to be decreasing over the 6-month time period, which is not expected
424B3
SEEL
Seelos Therapeutics Inc
29 Sep 23
Prospectus supplement
4:56pm
hour post dose)
Modified Observer’s Assessment of Alertness/Sedation Scale (“MOAA/S”)(7)
Maximum sedation (MOAA/S score < 5) occurred … condition.
Modified Observer’s Assessment of Alertness/Sedation Scale (MOAA/S) is a 6 point scale with a score of 5 defined as responds readily to name
424B5
rv73 o3bt
25 Sep 23
Prospectus supplement for primary offering
6:02am
8-K
EX-99.1
i41ddnhac 5i
20 Sep 23
Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
7:00am
8-K
EX-99.2
xruvux
20 Sep 23
Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
7:00am
8-K
EX-1.1
iupeeebsyvff8
12 May 22
Entry into a Material Definitive Agreement
8:31am
8-K
EX-10.1
2ja39vp t43u
24 Nov 21
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
8:20am
8-K
EX-4.1
njl6hyig
24 Nov 21
Entry into a Material Definitive Agreement
7:27am
8-K
EX-1.1
6bw3513emdyyacbvrxf
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am
424B5
4o5tt6z ea08sc9q9o4
21 May 21
Prospectus supplement for primary offering
12:00am
424B5
om4ttjx8d2clc5927jt
19 May 21
Prospectus supplement for primary offering
4:08pm